DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
Michael Brown submitted a Form 144 notice indicating an intended sale of 1,700 shares of Common Stock originally acquired as restricted stock. The filing shows transaction dates of 03/08/2026 (acquisition) and 03/16/2026 (sale activity), with the filing recorded on 04/15/2026.
Dexcom Inc ownership filing: The Vanguard Group filed an amendment stating it beneficially owns 0 shares of Dexcom common stock, representing 0% of the class. The amendment explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, where certain Vanguard subsidiaries will report disaggregated beneficial ownership.
Dexcom Inc. executive Michael Jon Brown, EVP and Chief Legal Officer, reported an open-market sale of 1,700 shares of common stock at $64.85 per share. The transaction occurred on March 16, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025.
After this sale, Brown directly holds 112,904 Dexcom shares. This figure includes 77,603 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029, reflecting a substantial continuing equity stake aligned with the company’s long-term performance.
DexCom Inc. Executive Chair Kevin R. Sayer reported routine equity compensation activity. He received a grant of 32,749 restricted stock units (RSUs) of DexCom common stock on March 8, 2026. These RSUs are scheduled to vest on the one-year anniversary of the grant date.
The filing also shows 32,498 shares of common stock withheld by DexCom at $68.10 per share to satisfy tax withholding and remittance obligations related to RSU settlement, which the company states does not represent a sale by Sayer. After these transactions, he directly holds 409,241 shares, including 106,972 unvested RSUs with various vesting schedules through March 8, 2028.
Dexcom Inc. EVP and CFO Sylvain Jereme reported a compensation-related equity transaction. He received a grant of 48,774 restricted stock units (RSUs) that will vest in three equal annual installments from the March 8, 2026 grant date. On the same date, 18,950 shares of common stock at $68.10 per share were withheld by Dexcom to satisfy tax obligations from RSU settlements, which the company states does not represent a sale by him. Following these transactions, he directly owns 153,292 Dexcom shares, including 92,794 unvested RSUs with various grant dates vesting through March 8, 2029.
DexCom Inc. executive Michael Jon Brown received a new equity award and had shares withheld for taxes. On March 8, 2026, he acquired 39,019 shares of Common Stock through a grant of restricted stock units (RSUs) that vest in three equal annual installments from the grant date.
On the same date, 23,325 shares of Common Stock were withheld by DexCom at $68.10 per share to cover tax withholding and remittance obligations in connection with RSU net settlement, which the disclosure notes does not represent a sale by Brown. After these transactions, he directly holds 114,604 shares of DexCom Common Stock, and this figure includes 77,603 unvested RSUs with various vesting schedules through March 8, 2029, as well as 255 shares acquired under the company’s Amended and Restated 2015 Employee Stock Purchase Plan.
Dexcom EVP and Chief HR Officer Sadie Stern received a grant of 39,019 restricted stock units (RSUs) of Common Stock on March 8, 2026. These RSUs are scheduled to vest in three equal annual installments from the grant date, with each RSU representing a right to receive one Dexcom share.
On the same date, 17,199 shares were withheld by the company at a price of $68.10 per share to cover tax obligations related to RSU settlement; this is explicitly described as not being a sale by Stern. Following these transactions, Stern directly holds 131,510 shares of Common Stock, including 77,603 unvested RSUs with various grants vesting through March 8, 2029.
Dexcom Inc. President, CEO, and Director Jacob Steven Leach received a grant of 104,516 restricted stock units (RSUs) on March 8, 2026. These RSUs vest in three equal annual installments from the grant date, with each RSU representing a right to one share of common stock.
On the same date, 19,757 shares of common stock at $68.10 per share were withheld to cover tax obligations related to RSU net settlement, which the company notes does not represent a market sale. After these transactions, Leach directly holds 421,810 shares of common stock, including 148,536 unvested RSUs spread across multiple grant years.
In addition, 47,296 shares are held indirectly through the Gregg Family Grandchildren's Trust UAD 12/30/2010, where Leach’s spouse serves as trustee.
Coleman Jon reported acquisition or exercise transactions in this Form 4 filing.
Dexcom EVP and Chief Commercial Officer Jon Coleman received a grant of 43,897 restricted stock units (RSUs) of Dexcom common stock. These RSUs vest in three equal annual installments from the March 8, 2026 grant date. After this award, Coleman holds 112,635 unvested RSUs in total, scheduled to vest through dates extending to 2029.